Anesthesiology 80:233, 1994 © 1994 American Society of Anesthesiologists, Inc. J. B. Lippincott Company, Philadelphia

A Really Long Sufentanil Infusion

To the Editor:-We were reading the September issue of ANES-THESIOLOGY when, by a cruel quirk of fate, Hurricane Emily suddenly snatched it from our white-knuckled grip. After a titanic struggle against the forces of nature and many near-death experiences, we, regrettably, were able to salvage only a single page (13A), containing part of the table of contents. While awaiting fresh ANESTHESIOLOGY copies to restock our soggy libraries, we wonder whether Albanese and colleagues had any unusual or unique complications when "sufentanil in a dose of 1 mg/kg administered over 6 months" was given to their unique subset of head trauma patients requiring long-term intracranial pressure monitoring.

> Jeffrey S. Kelly, M.D. John F. Butterworth IV, M.D. Department of Anesthesia

The Bowman Gray School of Medicine of Wake Forest University Medical Center Boulevard Winston-Salem, North Carolina 27157-1009 http://ass2.silverchair.com/http://ass2.sil

Anesthesiology 80:233-234, 1994 © 1994 American Society of Anesthesiologists, Inc. J. B. Lippincott Company, Philadelphia

Does Flumazenil Antagonize Midazolam-induced Depression of Ventilatory Response to Hypoxia?

To the Editor:- In their investigation of the effects of flumazenil on hypoxic respiratory drive following midazolam, Blouin et al.1 conclude that "flumazenil increases ventilation throughout a wide range of conditions . . . [and] may be useful in the treatment of benzodiazepine-induced ventilatory depression." The authors normalized the hypoxic drive slope data to the baseline premidazolam administration before data analysis, presumably to minimize the effect of day-to-day variability in the slope. We question whether this manipulation of the data was appropriate, because (as stated in the results) there was no significant difference between the baseline slopes, and these slopes were within the expected ranges reported in the literature.

The authors analyzed the slope data using analysis of variance with repeated measures and stated: "When all post-study drug determinations were considered, slopes were significantly greater after flumazenil than after placebo (P < 0.05); however, post boc testing could not attribute this difference to any particular observation times." The latter statement suggested that only marginal overall differences were found between the two treatment groups. We, therefore, calculated the actual mean slope data using the baseline slopes (1.04 and 1.45 $1 \cdot \min^{-1} \cdot \% Sp_{O_2}^{-1}$) and the fractions of baseline

that the difference between the groups might not have been statis tically significant had the authors analyzed the actual (rather that the normalized) data. In fact, the mean respiratory slopes of placebo patients returned to above their baseline values. Given the small sample size (n = 12), presentation of the actual data would have been more useful than the illustration showing fractions of baseline values. Examination of the real data of drug effect over time in each patient would have allowed more substantive comparison with oth studies, 2.3 reporting the effects of flumazenil on respiratory drive. 2

Blouin et al. also commented that, in contrast to their present study, the methods used in our previous work2 may not have controlled for the level of hypercarbic stimulation during the hypoxic challenge. We wish to clarify the authors' misunderstanding of our methodology. Our methods clearly ensured against a hypercarbic state, because the patient's Perco2 was kept in the normocarbic range (±1 mmHg). In contrast, hypercarbic and hypoxic stimulation are likely to have additive effects on the measured tidal volume and/or respiratory rate with the methods used by Blouin et al. We described the methodologic differences between the two studies in a letter to the editor4 published in 1990.